Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?
|
|
- Dwight Carson
- 5 years ago
- Views:
Transcription
1 Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late? Thomas Martin, Sophie Jose, Alicia Thornton, Natasha Martin, Caroline Sabin, Mark Nelson
2 Background Antiretroviral therapy (ART) in HIV/HCV co-infected individuals reduces risk of liver disease progression and may reduce risk of HIV transmission in MSM UK treatment guidelines have changed to reflect this, recommending ART initiation at higher CD4 counts in co-infected individuals Year CD4 < * * * HIV/HCV specific guidelines CD CD CD4 >500 Start ART Consider Defer However, the level of ART coverage and timing of ART initiation in this group is unknown
3 Key outcomes by calendar year 1. Proportion of people on ART (>1 drug at any time in year) 2. Mean HIV viral load (VL) and proportion with VL suppression 3. Median (IQR) most recent and nadir CD4 count* at ART initiation 4. Proportion of all CD4 counts* triggering ART initiation (within 6 months and before next CD4 count), according to CD4 strata 5. Probability of initiating ART by a given CD4 count* cumulative incidence estimated with death as a competing risk stratified by calendar year of positive HCV Ab test * Where confirmatory CD4 counts (within 45 days) were recorded, an average of these CD4 counts was used
4 Inclusion criteria Outcome Inclusion N 1. Proportion on ART 2. Mean HIV VL and proportion with VL suppression Exposed to HIV through sex between men (MSM) HCV Ab +ve* prior to 2012 >1 day follow up 1587 * Once positive, assumed to remain positive for the analysis
5 Inclusion criteria Outcome Inclusion N 1. Proportion on ART 2. Mean HIV VL and proportion with VL suppression Exposed to HIV through sex between men (MSM) HCV Ab +ve* prior to 2012 >1 day follow up Median (IQR) most recent & nadir CD4 at ART initiation 4. Proportion of CD4 counts triggering ART First HCV Ab +ve result in follow up whilst ART naïve >1 CD4 count between follow up start and ART initiation /follow up end 535 * Once positive, assumed to remain positive for the analysis Sensitivity analysis further excluding late presenters
6 Inclusion criteria Outcome Inclusion N 1. Proportion on ART 2. Mean HIV VL and proportion with VL suppression Exposed to HIV through sex between men (MSM) HCV Ab +ve* prior to 2012 >1 day follow up Median (IQR) most recent & nadir CD4 at ART initiation 4. Proportion of CD4 counts triggering ART First HCV Ab +ve result in follow up whilst ART naïve >1 CD4 count between follow up start and ART initiation /follow up end Probability of initiating ART by given CD4 count CD4 count >500 cells/mm 3 at first HCV Ab +ve result 208 * Once positive, assumed to remain positive for the analysis Sensitivity analysis further excluding late presenters
7 Characteristics at first positive HCV Ab N=1587 Age, mean (SD) 39 (8.2) Ethnicity, n (%) White Other/unknown Year of HCV diagnosis, n (%) < (85.7) 227 (14.3) 192 (12.1) 378 (23.8) 410 (25.8) 607 (38.2) Years diagnosed with HIV, median (IQR) 6.2 (2.2, 11.7) CD4 count [cells/mm 3 ], median (IQR) 461 (325, 630) HIV VL [log 10 copies/ml], median (IQR) 2.1 (1.7, 4.5) ART naïve, n (%) 673 (42.4)
8 Percent (%) Patients on ART, with VL suppression and mean VL in full study group On ART VL <200 copies/ml* Year * Based on last viral load available in each year
9 Percent (%) Patients on ART, with VL suppression and mean VL in full study group Viral Load (log 10 copies/ml) On ART VL <200 copies/ml* Mean VL 0 0 Year Mean of all viral loads over the year calculated for each person then averaged. Half the lower limit of detection for assay used if viral load undetectable.
10 CD4 count (cells/mm 3 ) Median (IQR) recent/nadir CD4 at ART initiation Most recent CD4 Nadir CD4 Year
11 CD4 count (cells/mm 3 ) Median (IQR) recent/nadir CD4 at ART initiation Most recent CD4 Nadir CD4 Year
12 Percent (%) % of CD4 counts that result in ART initiation, by CD4 strata <200 (n=177) (n=867) (n=1146) >500 (n=1245) Year ART initiations CD4 counts
13 Percent (%) % of CD4 counts that result in ART initiation, by CD4 strata <200 (n=177) (n=867) (n=1146) >500 (n=1245) Year ART initiations CD4 counts
14 Probability of initiating ART by a given CD4 count Median CD4 count at ART initiation (cells/mm 3 ) : : : 245
15 Probability of initiating ART by a given CD4 count Median CD4 count at ART initiation (cells/mm 3 ) : : : 320
16 Probability of initiating ART by a given CD4 count HIV mono-infected MSM ( ) Median CD4 at initiation 357 cells/mm 3 54% initiated ART by a CD4 of 350 cells/mm 3 97% initiated ART by a CD4 of 200 cells/mm 3
17 Conclusions ART coverage has increased and mean HIV VL decreased in the HIV/HCV co-infected MSM population over time Despite guidelines recommending ART at CD4 counts <350 cells/mm 3, the majority of patients had not initiated ART by this threshold between , when diagnosed at a higher CD4 count Reasons for delayed ART initiation are unknown; future studies should identify factors associated with this outcome More recent follow up needed to see if patterns remain and to assess more recent changes to guidelines The benefits of ART for HIV/HCV co-infected MSM should be emphasised to clinicians and patients
18 UK CHIC: Acknowledgements Research Department of Infection and Population Health, UCL Medical School: C Sabin, T Hill, A Phillips, S Jose, S Huntington, A Thornton Medical Research Council Clinical Trials Unit (MRC CTU): D Dunn, A Glabay Brighton and Sussex University Hospitals NHS Trust : M Fisher, D Churchill, N Perry, S Tilbury Chelsea and Westminster NHS Trust: B Gazzard, M Nelson, M Waxman, D Asboe, S Mandalia Kings College London School of Medicine, GKT Hospitals: F Post, H Korat, C Taylor, Z Gleisner, F Ibrahim, L Campbell Mortimer Market Centre, UCL Medical School: R Gilson, N Brima, I Williams Royal Free NHS Trust/UCL Medical School: M Johnson, M Youle, F Lampe, C Smith, A Phillips, R Tsintas, C Chaloner, S Hutchinson Imperial College Healthcare NHS Trust: J Walsh, N Mackie, A Winston, J Weber, F Ramzan Barts and the London NHS Trust: C Orkin, J Lynch, J Hand, C de Souza Homerton University Hospital NHS Trust: J Anderson, S Munshi, D Awosika The Lothian University Hospital NHS Trust: C Leen, A Wilson North Middlesex University Hospital NHS Trust: A Schwenk, J Ainsworth, C Wood, S Miller Health Protection Agency Centre for Infections: V Delpech North Bristol NHS Trust: M Gompels, S Allan University of Leicester NHS Trust: A Palfreeman, A Moore, L Fox South Tees Hospitals NHS Foundation Trust: D Chadwick, K Baillie Woolwich NHS Trust: S Kegg, P Main Coventry NHS Trust: S Allan St. George s NHS Trust: P Hay, M Dhillon York: F Martin, S Douglas UK CHIC is funded by the UK Medical Research Council
Dr Huw Price University College London
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Huw Price University College London 6-8 April 2011, Bournemouth International Centre Hepatitis B virus co-infection in HIV-infected patients
More informationPublisher Rights Statement: 2013 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Edinburgh Research Explorer The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations Citation for
More informationProfessor Caroline Sabin
Professor Caroline Sabin in partnership with Royal Free & University College Medical School London, UK COMPETING INTEREST OF FINANCIAL VALUE > 1,000 Statement Over the past five years, Caroline Sabin has
More informationBaseline renal function is an independent predictor of death and progression to severe chronic kidney disease
Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease Fowzia Ibrahim, Lisa Hamzah, Rachael Jones, Loveleen Bansi, Dorothea Nitsch, Caroline Sabin
More informationFirst-line NNRTI to second-line PI/r
Outcomes of 2 nd line ART First-line NNRTI to second-line PI/r Laura Waters, David Asboe,, Anton Pozniak, Loveleen Bansi, Chloe Orkin, Erasmus Smit, Esther Fearnhill & Andrew Phillips. UK Resistance Database
More informationHLA B M 5701 status, disease progression, and response to antiretroviral therapy
CONCISE COMMUNICATION HLA B M 5701 status, disease progression, and response to antiretroviral therapy The UK Collaborative HIV Cohort Study Steering Committee Objective: In addition to hypersensitivity
More informationImpact on life expectancy of HIV-1 positive individuals of CD4 R cell count and viral load response to antiretroviral therapy
Impact on life expectancy of HIV-1 positive individuals of CD4 R cell count and viral load response to antiretroviral therapy Margaret T. May a, Mark Gompels b, Valerie Delpech c, Kholoud Porter d, Chloe
More informationDr Melanie Rosenvinge
18 th Annual Conference of the British HIV Association (BHIVA) Dr Melanie Rosenvinge St George s Hospital NHS Trust, London 1820 April 2012, The International Convention Centre, Birmingham A multicentre
More informationClinical Infectious Diseases Advance Access published February 16, 2016
Clinical Infectious Diseases Advance Access published February 16, 2016 1 Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK epidemiological
More informationUC San Diego UC San Diego Previously Published Works
UC San Diego UC San Diego Previously Published Works Title Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United
More informationBaseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients
Original Investigation Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, 1 Lisa Hamzah, MRCP, 1 Rachael Jones, MRCP, 2 Dorothea
More informationResponse to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
Huntington et al. BMC Infectious Diseases 2014, 14:127 RESEARCH ARTICLE Open Access Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy
More informationMiss Jane Rowlands. Chelsea and Westminster Hospital, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Miss Jane Rowlands Chelsea and Westminster Hospital, London 1-4 April 2014, Arena and Convention Centre Liverpool Multi-centre open-label study of switching
More information38% of child bearing women with HIV in the UK would like to breastfeed PACIFY STUDY Farai Nyatsanza Imperial College Healthcare NHS Trust
38% of child bearing women with HIV in the UK would like to breastfeed PACIFY STUDY Farai Nyatsanza Imperial College Healthcare NHS Trust Background Breastfeeding is accepted as vital strategy due to its
More informationImproved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir Sophie Jose a, Mark Nelson b, Andrew Phillips a, David Chadwick c, Roy Trevelion d, Rachael
More informationC Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;
Switching from Kivexa [KVX] (ABC/3TC) + Efavirenz [EFV] to [ATR] (EFV/FTC/TDF) Reduces Cholesterol in Hypercholesterolaemic Subjects: Primary Endpoint Results of a 24- Week Randomised Study C Orkin, 1
More informationRisk factors and outcomes for the Q151M and T69 insertion HIV 1 resistance mutations in historic UK data
https://doi.org/10.1186/s12981-018-0198-7 AIDS Research and Therapy RESEARCH Open Access Risk factors and outcomes for the Q151M and T69 insertion HIV 1 resistance mutations in historic UK data Oliver
More informationPregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy Susie Huntington a,b, Claire Thorne a, Marie-Louise Newell c, Jane Anderson d, Graham P. Taylor e,
More informationBHIVA Best of CROI Feedback Meetings BHIVA Best of CROI Feedback Meetings 2012
BHIVA Best of CROI Feedback Meetings London North East England North West England Edinburgh Birmingham BHIVA Best of CROI Feedback Meetings 2012 Introduction Simon Collins HIV i-base 1 Community perspectives
More informationHepatitis B, hepatitis C, and mortality among HIV-positive individuals
Hepatitis B, hepatitis C, and mortality among HIV-positive individuals Alicia C. Thornton, Sophie Jose, Sanjay Bhagani, David Chadwick, David Dunn, Richard Gilson, Janice Main, Mark Nelson, Alison Rodger,
More informationTrends in transmitted drug resistance to HIV-1 in the UK since 2010
Trends in transmitted drug resistance to HIV-1 in the UK since 2010 Anna Tostevin, Ellen White, Sara Croxford, Valerie Delpech, Ian Williams, David Dunn on behalf of the UK HIV Drug Resistance Database
More informationThe REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics
The REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics Dr Fiona Burns on behalf Dr Alison Evans and the REACH team Research Department of Infection and Population
More informationDr Kate Childs. King s College Hospital NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Kate Childs King s College Hospital NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool Decrease in both IP-10 and 25(OH)D
More informationAcute Hepatitis C in the PROUD pilot study
Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study PROUD Pilot Study PRe-exposure
More informationDownloaded from:
Lampe, F; Speakman, A; Sherr, L; Phillips, A; Collins, S; Gilson, R; Johnson, M; Fisher, M; Wilkins, E; Anderson, J; Daskalopoulou, M; Edwards, S; McDonnell, J; Perry, N; Jones, M; O Connell, R; Lascar,
More informationCirrhosis and liver transplantation in patients co infected with HIV and hepatitis B or C: an observational cohort study
Infection (2017) 45:215 220 DOI 10.1007/s15010-016-0976-x BRIEF REPORT Cirrhosis and liver transplantation in patients co infected with HIV and hepatitis B or C: an observational cohort study Charlotte
More informationA DIRECT COMPARISON OF TWO DENSELY SAMPLED HIV EPIDEMICS: THE UK AND SWITZERLAND.
A DIRECT COMPARISON OF TWO DENSELY SAMPLED HIV EPIDEMICS: THE UK AND SWITZERLAND. Manon L. Ragonnet-Cronin 1 *, Mohaned Shilaih 2,3 *, Huldrych Günthard 2,3, Emma B. Hodcroft 1, Jürg Böni 3, Esther Fearnhill
More informationBHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012
BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 30 th April 2012 Writing Group Dr Ian Williams Senior Lecturer, University College London and Honorary Consultant
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationBritish HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
DOI: 10.1111/j.1468-1293.2012.01029_1.x British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 Writing Group Dr Ian Williams Senior Lecturer, University
More informationCHERUB Collaborative HIV Eradication of Reservoirs: UK BRC (
CHERUB Collaborative HIV Eradication of Reservoirs: UK BRC (www.cherub.uk.net) The effect of time to viral suppression at primary HIV infection on long term immunological recovery BHIVA Spring Conference
More informationAbacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study
Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Collins Iwuji, Duncan Churchill, Yvonne Gilleece, Martin Fisher Brighton and
More informationDr Sonia Raffe. Royal Sussex County Hospital, Brighton. 21 st Annual Conference of the British HIV Association (BHIVA)
21 st Annual Conference of the British HIV Association (BHIVA) Dr Sonia Raffe Royal Sussex County Hospital, Brighton 21-24 April 2015, The Brighton Centre 21 st Annual Conference of the British HIV Association
More informationDOI: /hiv British HIV Association HIV Medicine (2014), 15 (Suppl. 1), 1 85
DOI: 10.1111/hiv.12119 2014 British HIV Association HIV Medicine (2014), 15 (Suppl. 1), 1 85 British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
More informationAntiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider?
Antiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider? Saturday 22nd March 2014, Mumbai, India Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn,
More informationTreatment as prevention in HCV: Modelling impact among people who inject drugs and HIV+ men who have sex with men
Treatment as prevention in HCV: Modelling impact among people who inject drugs and HIV+ men who have sex with men Natasha Mar)n, Peter Vickerman, Ma/ Hickman School of Social and Community Medicine, University
More informationDownloaded from:
Iwuji, CC; Churchill, D; Gilleece, Y; Weiss, HA; Fisher, M (2013) Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. Bmc Public Health, 13. ISSN 1471-2458
More informationRecent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom
DOI: 10.1111/hiv.12414 ORIGINAL RESEARCH Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom A Tostevin, 1 E White, 1 D Dunn, 1 S Croxford, 2 V Delpech, 2 I Williams,
More informationSafety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients
Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients Amy Moore, Sonali Sonecha, Tristan Barber, Anton Pozniak, David Asboe, Marta Boffito
More informationUK clinicians approach to ART in primary HIV infection; comparison with the BHIVA guidelines
UK clinicians approach to ART in primary HIV infection; comparison with the BHIVA guidelines Dr. Julie Fox Victoria Parsons 1, Sarah Fidler 2, Naomi Fitzgerald 3, Simon Collins 4, Andrew Phillips 1, Richard
More informationPOPPY. Pharmacokinetic and clinical observations in people over 50
POPPY Pharmacokinetic and clinical observations in people over 50 Self- reported symptoms of insomnia and objective measures of sleep quality in people living with HIV and comparable controls D. De Francesco
More informationTHIRD JOINT CONFERENCE OF BHIVA AND BASHH Dr Laura Waters. Mortimer Market Centre, London. 1-4 April 2014, Arena and Convention Centre Liverpool
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Laura Waters Mortimer Market Centre, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Laura
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More information25th Annual Conference of the British HIV Association Bournemouth 2019
25th Annual Conference of the British HIV Association Bournemouth 2019 Declarations Dr Ming Lee has no conflicts of interests relevant to this presentation. Dr Ming Lee Dr David Chadwick In 2016 around
More informationUK HIV Drug Resistance Database. David Dunn MRC Clinical Trials Unit
UK HIV Drug Resistance Database David Dunn MRC Clinical Trials Unit Background Resistance tests performed as part of routine clinical care form a valuable scientific resource UK HIV Drug Resistance Database
More informationDr Anna Herasimtschuk
19 th Annual Conference of the British HIV Association (BHIVA) Dr Anna Herasimtschuk Imperial College London 16-19 April 213, Manchester Central Convention Complex Therapeutic immunisation in conjunction
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Duncan Churchill Royal Sussex County Hospital, Brighton COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Duncan Churchill
More informationNational Haemoglobinopathy Registry. Annual Report 2015/16. mdsas
National Haemoglobinopathy Registry Annual Report 2015/16 mdsas National Haemoglobinopathy Registry Annual Report (2015/16) 3 1 Introduction CHAPTER 1 This 2015/16 data update follows the same format as
More informationTreatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK
Treatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK Dr Valerie Delpech Health Protection Agency, London (Public Health England) Outline! Brief overview Science,
More informationAntiviral Therapy 2013; 18: (doi: /IMP2329)
Antiviral Therapy 2013; 18:213 219 (doi: 10.3851/IMP2329) Original article Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the
More informationHIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3, Nicola Robinson 1,2,3, Sarah Fidler 4, Jonathan
More informationNational Diabetes Audit Programme Update LONDON REGION DIABETES EVENT 18 JULY 2017
National Diabetes Audit Programme Update LONDON REGION DIABETES EVENT 18 JULY 2017 NDA Reports NDA Insulin Pump Audit 2015-16 NDA Complications and Mortality 2015-16: Standard analysis Longitudinal analysis
More informationProfessor Mark Nelson. Chelsea and Westminster Hospital, London, UK
Professor Mark Nelson Chelsea and Westminster Hospital, London, UK Treatment should be prioritized Treatment Indicated All naive and experienced pts with liver disease Prioritized Pts with fibrosis (F3)
More informationNational Haemoglobinopathy Registry. Annual Report 2017/18
National Haemoglobinopathy Registry Annual Report 2017/18 National Haemoglobinopathy Registry Annual Report (2017/18) Compiled by Mark Foster MDSAS 3 1 Introduction CHAPTER 1 The 2017/18 Annual Report
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationMENOPAUSAL SYMPTOMS ARE ASSOCIATED
MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN WOMEN LIVING WITH HIV Shema Tariq, Fiona Burns, Alexandra Rolland, Caroline Sabin, Lorraine Sherr, Richard Gilson (on behalf of the PRIME
More informationSuicide among people diagnosed with HIV in England and Wales compared to the general population
Suicide among people diagnosed with HIV in England and Wales compared to the general population Sara Croxford, Meaghan Kall, Fiona Burns, Andrew Copas, Alison Brown, Sarika Desai, Ann K Sullivan, Andrew
More information14 January Dear Endometriosis Centre Lead
14 January 2017 Dear Endometriosis Centre Lead Thank you for your continued support of the Endometriosis Centres Project. With this letter is the summary of data from all the centres for 2016 as we have
More informationDr Charlotte-Eve Short
19 th Annual Conference of the British HIV Association (BHIVA) Dr Charlotte-Eve Short Imperial College London 16-19 April 2013, Manchester Central Convention Complex Elevated leukocyte adhesion marker
More informationThe importance of cohort collaborations for guiding clinical management of individuals with HIV infection
The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College
More informationPSYCHOLOGICAL BURDEN AND THE IMPACT ON
PSYCHOLOGICAL BURDEN AND THE IMPACT ON ENGAGEMENT WITH CARE AMONG ETHNICALLY DIVERSE OLDER WOMEN WITH HIV 4 th April 2019 Danielle Solomon 1, Shema Tariq 1, Jon Alldis 1, Fiona Burns 1, Richard Gilson
More informationASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS
ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg,
More informationPrevention of Perinatal HIV Infection:
FINAL PROGRAMME Prevention of Perinatal HIV Infection: Aiming for zero transmission A multidisciplinary conference for obstetricians, gynaecologists, HIV physicians, midwives and allied healthcare professionals
More informationHIV in primary care. How effective and safe are HIV testing and care in General Practice?
HIV in primary care How effective and safe are HIV testing and care in General Practice? Dr Werner Leber GP and Clinical Lecturer in Primary Care and Public Health Queen Mary, University of London werner.leber@nhs.net
More informationAnal cancer prevention strategies including screening for HPV-related diseases in HIV-positive patients
Anal cancer prevention strategies including screening for HPV-related diseases in HIV-positive patients Charles JN Lacey, Centre for Immunology and Infection, University of York, York, United Kingdom One
More informationHIV in London: A Complexity Challenge
HIV in London: A Complexity Challenge Professor Jane Anderson (Homerton University Hospital) and Dr David Asboe (Chelsea and Westminster Hospital) NHS England Clinical Reference Group for HIV Representatives
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationLack of association between use of efavirenzand death from suicide: the D:A:D Study
Lack of association between use of efavirenzand death from suicide: the D:A:D Study Colette Smith, Lene Ryom, Antonellad ArminioMonforte, Peter Reiss, Amanda Mocroft, Wafaa el Sadr, Rainer Weber, Mathew
More informationMartel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich DT, Branch AD
On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients Martel-Laferrière V, Brinkley S, Bichoupan
More informationLife after CHIPS: CHIPS+ and AALPHI update. Marthe Le Prevost AALPHI Research Nurse MRC Clinical Trials Unit at UCL
Life after CHIPS: CHIPS+ and AALPHI update Marthe Le Prevost AALPHI Research Nurse MRC Clinical Trials Unit at UCL Talk outline CHIPS+ introduction progress to date AALPHI recruitment update cohort characteristics
More informationTesting for blood borne viruses in the emergency department of a large London hospital
Testing for blood borne viruses in the emergency department of a large London hospital Bradshaw D 1, Rae C 1, Turner R 1, Pickard G 2, Rezende D 2, Pillay K 2, Patel D 2, Roberts P 1, Foxton M 1, Sullivan
More informationCompassionate supply of Antiretrovirals
Characteristics of patients receiving compassionate supply of antiretroviral medications and associated medication costs in a Toronto HIV specialty clinic Deborah Yoong, BScPhm, PharmD. Mark Naccarato,
More informationProfessor Sheena McCormack
21 st Annual Conference of the British HIV Association (BHIVA) Professor Sheena McCormack MRC Clinical Trials Unit at UCL, London 21-24 April 2015, The Brighton Centre 21 st Annual Conference of the British
More informationGraham Cooke. Imperial College & Imperial College NHS Trust. NIHR Research Professor. BHIVA meeting October 2018
Graham Cooke Imperial College & Imperial College NHS Trust NIHR Research Professor BHIVA meeting October 2018 @grahamscooke The Big Picture Scaling up the global response The role of microelimination The
More informationHIV in the United Kingdom
HIV in the United Kingdom Valerie Delpech and Alison Brown on behalf of the HIV and AIDS Reporting Section National Infection Service Public Health England Released 15 December 2017 Undetectable=Untransmittable
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More informationMANITOBA HIV REPORT 2015
MANITOBA HIV REPORT 2015 The Manitoba HIV Program provides information, specialized care, treatment, and support to approximately 1,250 people living with HIV across the province. The Program has two Winnipeg-based
More informationTotal Payment for sponsored attendances by Healthcare Professionals: 182,677 ( 153,923 in 2013)
Gilead Sciences Ltd. 280 High Holborn London WC1V 7EE 31st March 2015 Relationships with Healthcare Professionals in the United Kingdom Gilead Sciences makes payments to Healthcare Professionals for consultancy
More informationDr Alison Brown. Public Health England. 15 th Annual Conference of the National HIV Nurses Association (NHIVNA)
15 th Annual Conference of the National HIV Nurses Association (NHIVNA) Dr Alison Brown Public Health England 27-28 June 2013- The International Convention Centre, Birmingham The UK HIV Epidemic: where
More informationCommunity oriented studies. New perspectives
Community oriented studies. New perspectives Swiss HIV Cohort Study Increased Viral Load Suppression in HIV+ Persons on ART Cohort size: 4624 4852 5045 5279 5556 5830 6121 6418 6526 100 Percent of individuals
More informationManagement of Severe Primary HIV Infection
Management of Severe Primary HIV Infection Martin Fisher Brighton and Sussex University Hospitals Outline What is severe PHI? How frequent is severe PHI? Is this occurring more frequently? Is severe PHI
More informationHIV surveillance in Northern Ireland 2016
HIV surveillance in Northern Ireland 2016 Contents Page 1 Surveillance arrangements 3 2 Introduction and key points 4 3 Trend information 5 - New diagnoses Age and gender Route of transmission CD4 surveillance
More information21 st BHIVA Brighton th April Dr Christopher Wood North Middlesex University Hospital
21 st BHIVA Brighton 21-24 th April 2015 Dr Christopher Wood North Middlesex University Hospital Mortality by cause of death and sex: E&W, 1997-2012 2 Mortality and causes of death among women living with
More informationDispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin
Dispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), UCL, London, UK Disclosures I have
More informationHIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London
HIV/HCV co-infected patients should be prioritised for HCV treatment Sanjay Bhagani Royal Free Hospital/UCL London Also requires other resources What should a prioritisation process Life-saving at this
More informationDr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)
19 th Annual Conference of the British HIV Association (BHIVA) Dr Manisha Yapa Chelsea and Westminster Hospital, London 16-19 April 2013, Manchester Central Convention Complex The impact of switching to
More informationDr Lucy Garvey. Imperial College Healthcare NHS Trust, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Lucy Garvey Imperial College Healthcare NHS Trust, London 18-20 April 2012, The International Convention Centre, Birmingham Microglial
More informationHIV in Pregnancy. Final Programme. Joint RCOG/BHIVA Multidisciplinary Conference. Friday 20 January 2012
Final Programme Joint RCOG/BHIVA Multidisciplinary Conference HIV in Pregnancy Friday 20 January 2012 Royal College of Obstetricians and Gynaecologists London Sponsored by INTRODUCTION Dear Colleague We
More informationWHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean
WHO recommendations for HIVDR surveillance and their application in Latin America and the Caribbean Giovanni Ravasi Pan-American Health Organization, Brazil ravasigi@paho.org Regional Consultation on HIV
More informationCo-infection, Opportunistic Infections and Malignancies
BHIVA Best of CROI Feedback Meetings London North East England North West England Edinburgh Birmingham BHIVA Best of CROI Feedback Meetings 2012 Co-infection, Opportunistic Infections and Malignancies
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationClinical Infectious Diseases Advance Access published October 9, Hepatitis C core antigen testing: a reliable, quick and potentially
Clinical Infectious Diseases Advance Access published October 9, 2014 1 Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction
More informationAntiviral Therapy 14:
Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationMet and unmet health, welfare and social needs of people accessing HIV services Findings from the Positive Voices 2017 survey
Met and unmet health, welfare and social needs of people accessing HIV services Findings from the Positive Voices 2017 survey Meaghan Kall Public Health England on behalf of the Positive Voices study group
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationChanges in viral suppression status among US HIV-infected patients receiving care
CONCISE COMMUNICATION Changes in viral suppression status among US HIV-infected patients receiving care Nicole Crepaz a, Tian Tang b, Gary Marks a and H. Irene Hall a Objective: To examine changes in viral
More informationFactors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa
Factors associated with unsuppressed viral load in HIV-1 infected patients on 1 st line antiretroviral therapy in South Africa Dvora Joseph Davey 1, 2, PhD, Zulfa Abrahams 2, PhD 1 BroadReach, South Africa
More information